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was 29.2%. In patients with endoscopic remission at Week 10, the IBDQ remission
rate was 69.7% compared with 33.3% in patients not reaching endoscopic remis-
sion. Similar results were observed at Week 54. CONCLUSIONS: Treatment with
CZP at the recommended dose resulted in substantial improvement in HRQoL at 10
and 54 weeks of therapy, measured by the IBDQ. Higher rates of IBDQ remission
were associated with endoscopic remission compared with nonremission, war-
ranting further evaluation of CZP therapy on HRQoL in CD. †Dr Lémann died on
August 26, 2010. We mourn the loss of our esteemed colleague.
Health Care Use & Policy Studies – Consumer Role in Health Care
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KENYA’S VILLAGE AGING INSENSITIVITY TO AGING POLICIES
Nyabade G
Go Fishnet Youth Project, Kisumu, Nyanza, Kenya
OBJECTIVES: Since independence in Kenya in 1963, there has been great challenges
on policy making with regards to the village elderly and ageing. Inspite of our
current advocacies, sensitization and awareness programmes being carried out by
local non governmental humanitarian bodies and faith based entities, Kenyan el-
derly and ageing men and women lack government concern, services and new
policies on especially the ageing village vulnerable ill-health policy and services in
their life insurance The aim and purpose of my paper is to highlight worthy ap-
proaches and to identify areas of need as a priority in overcoming the impasse in
Kenyan policy on ageing and health. METHODS: We conducted a village research
on a door to door basis on policy and health development through Questionare as
part of a research project on dimensions and actions of health in old age in rural
communities in western Kenya and its policy implications. RESULTS: Five very
sensitive areas of evidence of lack of awareness and government lack of action to
the aged and ageing groups were highlighted. And required to (1) sensitize and give
strength to the case on why action on old age-related health should be pursued,
and (2) what action be taken to bring to light the uncertainties of the aged and
ageing groups in Kenyas most forgotten rural insensitive communities.
CONCLUSIONS: A continued formal research system on the five areas is essential
to promote awareness of policies on aged and ageing groups in the insensitive
villages and advocacy towards their ignorance and plight on matters related to
their life insurance, policy making and advancement towards scientific debate on
ageing and their health in the global community.
Health Care Use & Policy Studies – Disease Management
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OBJECTIVES: Cost of prescriptions is a large portion of the nation’s health care
expenditure. In 2007, the Kaiser Family Foundation estimated total prescription
costs to be $202 billion, demonstrating a large burden to the US economy. This
study evaluates determinates of non-opioid analgesic (NOA) prescribing patterns
in the USA from the National Ambulatory Medical Care Survey (NAMCS) from
2002-2007. METHODS: NOA prescribing trends were determined using drug codes
from NAMCS data. The data was collected on patients greater than 18 years, with
ICD-9-CM codes for chronic-non-cancer pain as reasons for office visits. The study
used cross-sectional analysis. A logistic model reported determinants of NOA in
the study population. RESULTS: A total of 22,967 analgesic prescriptions were pre-
scribed from 2002-2007 for men (37%) and women (63%) 18 years or older. Men were
1.46 times more likely (p0.05) to receive NOA than Women. Medicare and Medic-
aid patients were 42% (p0.01) and 44% (p0.01) more likely to receive NOA than
patients with other insurance types. Patients seen by primary care physicians
(PCPs) were 56% (p0.05) more likely to receive NOA than by non-PCPs. Low back
pain (LBP) patients were 60% more likely to get NOA prescribed than patients with
non-LBP. Geographical location was a statistically insignificant factor relating to
the likelihood of a being prescribed NOAs. Socio-economic, education, lifestyle,
diet, age group, ethnicity, and mental health status were also found to be
insignificant. CONCLUSIONS: Men, patients with Medicare, Medicaid, and LBP
were more likely to receive prescriptions for NOA. Physicians managing patients at
risk of receiving NOA, reported in our results, may benefit from seeking evidence
based policy for maximizing pain control in a cost-effective way.
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A REVIEW OF BREAST CANCER (BC) CARE AND OUTCOMES IN LATIN AMERICA
& CARIBBEAN (LAC)
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OBJECTIVES: Provide an overview of the burden of BC and of BC care and outcomes
in LAC.METHODS: Review of literature (PubMed, LILACS, SCIELO), public databases
(Globocan 2002 & 2008, CEPALSTAT, DIRAC, PAHO, WHOSYS, etc) and conference
presentations (ASCO, ISPOR). Latin-American experts and patient organizations
were surveyed. RESULTS: A total of 114,900 women present with and 37,000 die of
BC annually in LAC. BC exhibits the highest incidence and mortality of all cancers,
is steadily increasing and is expected to double by 2030. Age is the principal risk
factor. High incidence in Argentina and Uruguay (ASR 74-91/100,000) and younger
age at diagnosis and death (mean 57y) in Peru, Mexico, Colombia and Brazil trans-
late into a heavy burden. LAC’s low 5-year survival (70-75%) is partly because
30-40% patients are diagnosed in metastatic phases III and IV. However, BC mor-
tality-to-incidence ratios (MIR) improvements are noticeable when comparing
MIR2002 vs. MIR2008. Best MIRs are registered in Argentina, Uruguay and Chile.
Costa Rica shows the most progress; Brazil, Mexico and Panama have not improved
significantly. Suboptimal prevention policies; vast inequalities in access to diagno-
sis and treatment, a fragmented organisation and management of BC care, and
poor uptake of evidence-based best practices were observed. Universal healthcare
coverage is not the rule in LAC and, even in those countries where access to BC
health services is guaranteed by law; resources are insufficient. Availability of BC-
specialized surgeons, waiting times, node clearance policy and access to breast
reconstruction vary greatly across countries and between public and private set-
tings. Radiotherapy equipment is insufficient (except Uruguay, Chile, Venezuela).
All modern systemic therapies are available but some not widely diffused for cost
considerations. Palliative care is developing but, despite great efforts, many prob-
lems persist. CONCLUSIONS: Women go undiagnosed, uncared for or treated with
suboptimal therapies; which results in high morbidity and associated societal
costs.
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SIGNIFICANT DECREASE IN THE HUNGARIAN HEALTH INSURANCE
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OBJECTIVES: At the end of 2006, there was an important reform in the Hungarian
pharmaceutical market, including serious changes in the health insurance reim-
bursement of medicines. The aim of our study is to analyze the changes in the
Hungarian health insurance pharmaceutical budget between 2006-2009.
METHODS: Data were derived from the nationwide administrative dataset of the
National Health Insurance Fund Administration (OEP), the only health care financ-
ing agency in Hungary. We analyzed the changes of the pharmaceutical budget
between 2006-2009. Results are given in Hungarian Forint (HUF), US dollars (USD)
and Euro (EUR). The annual average currency exchange rates were applied accord-
ing to the data of the Central Bank of Hungary. RESULTS: In the first year, the
Hungarian pharmaceutical budget decreased from 388.7 billion HUF (2006) to 323.6
billion HUF (2007) by 65.1 billion HUF (16.7 %). This decrease was a bit moderate
both in Euro (0.18 billion EUR, 12.4 %) and in USD dollar (0.1 billion USD, 4.7 %) due
to the stronger Hungarian currency. For 2009, the pharmaceutical budget slightly
increased compared to 2007 up to 343.2 billion HUF which resulted in a decrease
from 2006 to 2009 by 45.5 billion HUF (11.7 %). The decrease between 2006-2009 was
more significant both in Euro (0.25 billion EUR, 16.8 %) and in USD dollar (0.15 billion
USD, 8.1 %) due to the weakened Hungarian currency. CONCLUSIONS: Due to the
reform of the whole Hungarian pharmaceutical market, the Hungarian health in-
surance pharmaceutical budget significantly decreased between 2006-2009. This
decrease was moderate in EUR or USD between 2006-2007, however between 2006-
2009 it became higher as the Hungarian currency weakened compared to EUR or
USD during the world economic crisis.
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MODELO TEORICO DE UN CONSUMIDOR: SELECCION ENTRE UN BIOSIMILAR Y
UN BIOTECNOLOGICO DE PATENTE BASADO EN PREFERENCIAS
Lechuga D
ITAM, México, D.F., México
OBJECTIVOS: Realizar un análisis teórico de las preferencias del paciente derivado
de la elección entre dos bienes: un medicamento biotecnológico de patente y un
medicamento biosimilar. METODOLOGÍAS: Suponemos que son bienes sustitutos
perfectos, pues el paciente no puede consumir los dos bienes al mismo tiempo,
debe elegir entre uno u otro. Definimos la función de utilidad del paciente como
U(BT,BS)aBTbBS. Donde, BT es el Biotecnológico de patente, BS Biosimilar, a es la
seguridad y eficacia del medicamento BT y b seguridad y eficacia del medicamento
BS. Entre más seguro y eficaz sea el medicamento el paciente lo prefiere más. Entre
mayor sea U su estado de salud es mejor. Suponemos que BT tiene estudios clínicos
confiables que demuestran su seguridad y eficacia y que BS no presenta estudios
clínicos y no se sabe su seguridad y eficacia real, por lo tanto BT es preferido, es
decir ab. El paciente posee una restricción presupuestal determinada por la ec-
uación yPBTBTPBSBS. Derivado de las inversiones en estudios clínicos supo-
nemos que PBTPBS. La tasa marginal de sustitución está determinada por la pen-
diente -a/b, es decir que el paciente sacrificará una unidad de BT por b/a unidades
del bien BS. Dada la restricción presupuestal, la pendiente y tasa de sustitución
objetivo es -PBT/PBS. RESULTADOS: De acuerdo a las preferencias del consumidor,
su consumo óptimo se determinan de acuerdo a lo siguiente, si PBT/PBSa/b solo
consumirá BT, si PBT/PBSa/b entonces el paciente solo consumirá BS, y si PBT/
PBSa/b el paciente está indiferente entre consumir BT o BS. CONCLUSIONES:
Podemos concluir que las preferencias del paciente son sensibles al precio y a la
seguridad y eficacia del medicamento. Entre más seguro y eficaz sea BT el paciente
lo prefiere y estará dispuesto a pagar más.
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OBJECTIVOS: Analizar las actualizaciones hechas al cuadro Básico y Catálogo de
Medicamentos (CBM) del Sector Salud en el periodo 2006-2010. Analizar el grado de
apego al CBM en las compras de medicamentos realizadas por diferentes institu-
ciones del sector público de salud en el periodo 2006-2009. METODOLOGÍAS: Se
identificaron en el Diario Oficial de la Federación las actualizaciones (inclusiones,
modificaciones y exclusiones) realizadas al CBM en el periodo de 2006-2010. Se
analizó información de compra pública de medicamentos para el periodo 2006-
2009. Para el procesamiento de la información se construyó una base de datos con
la información en el programa estadístico Stata. RESULTADOS: En el periodo 2006-
2010 se han realizado 24 actualizaciones al CBM. En total se realizaron 359 cambios
de los cuales el 39% corresponden a inclusiones, 53% actualizaciones y un 8% a
exclusiones. El 78% de los cambios fueron realizados al Cuadro Básico de Insumos
para el primer nivel de atención y el 22% restante al Catálogo de Insumos para el
segundo y tercer nivel. Se identificó que aproximadamente sólo se compró el 80%
del total de medicamentos listados en el CBM además de que se identificaron
medicamentos cuyas presentaciones y/o sustancias activas no se encuentran lis-
tados en el CBM. CONCLUSIONES: La creación del CBM siguió tres objetivos funda-
mentales: promover la presentación uniforme para los medicamentos que adqui-
era el sector público; servir como instrumento de orientación para una prescripción
adecuada así como evitar la dispersión de criterios institucionales; y servir como
guía para la adquisición correcta de medicamentos. Los resultados encontrados
dan evidencia de que estos objetivos no se están cumpliendo por lo que es necesa-
rio reordenar y analizar el contenido y uso que se da al CBM en las instituciones del
sector público.
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IMPACT OF GLOBAL HEALTH CARE REFORMS ON PRICING, ACCESS AND
HEALTH ECONOMICS AND OUTCOMES STRATEGY
Aggarwal S
PAREXEL Consulting, Bethesda, MD, USA
OBJECTIVES: During 2009-2010 major health care reforms were proposed and im-
plemented in a number of nations, for example, Affordable Care Act in the US,
AMNOG in Germany, HSPT in France, KVG in Switzerland and NHS proposed re-
form in the UK. These reforms have major implications on pricing, market access
and HEOR strategy for drug and device products. METHODS: To understand the
implications of these trends, we analyzed 2009-2010 reform bills and proposed
changes worldwide. Additionally, we interviewed public and private payers, key
opinion leaders and payer-influencers to understand implications of these reforms
on drug and device manufacturers. RESULTS: The global healthcare landscape is
expected to undergo significant change during 2011-2015. In the US, government
will play increased role as a single payer, especially with–Medicare, Medicaid and
CHIP programs– which will cover 114 million Americans, at a cost of $784 billion. In
Germany, AMNOG bill marked the end of free drug pricing and would lead to
increased insurance premiums (now 15.5% of wages). In the UK, NHS has proposed
to replace PCTs with 500-1000 GP-led consortia and use value-based pricing for
expensive drugs and devices. Overall, payers view that in the future, health eco-
nomic assessments would play critical role in pricing, coverage and reimburse-
ment of branded products. CONCLUSIONS: This analysis shows that global health-
care landscape is expected to undergo significant change during 2011-2015.
Discussions with payers, KOLs and payer-influencers highlights increased impor-
tance of HEOR data in the future.
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MEASURING ADHERENCE TO DRUG TREATMENT IN MEXICAN PATIENTS: A
SYSTEMATIC REVIEW
Uc-Coyoc R, Pérez-Reynaud AG, Coello-Reyes LA, Rodriguez-Díaz Ponce MA
Instituto Mexicano del Seguro Social, México, D.F., México
OBJECTIVES: Measuring the level of adherence to drugs is relevant to assess the
clinical benefits of prescribed treatments. Adherence can be defined as the extent
to which a patient intake of medicines coincides with the medical prescription. The
purpose of this study is to review the degree of adherence to drugs among Mexican
patients as part of the overall medical therapy. METHODS: A systematic review
was performed to retrieve information on quantity measures of drug adherence to
medical treatments in Mexico. Key words such as “treatment and patient adher-
ence,” “drug compliance” and “drug utilization” were searched in Pub Med, Med-
line, Embase, Medic Latina, and the Cochrane Library of Systematic Reviews from
1998 to 2010. RESULTS: Few published studies in Mexico quantify the extent of
adherence to drugs among Mexican patients. Most of these studies measured drug
adherence in three chronic diseases: diabetes, HIV/AIDS, and rheumatoid arthritis.
These were carried out at the regional level with patients from public health insti-
tutions. The main methods used were pill-count, questionnaires, and interviews
with patients. Adherence to diabetes medication reported frequencies in the range
of 17.2%- 54.2%, while in antiretroviral treatment for HIV/AIDS, the range was from
42% to 85.3%. One study reported adherence to disease-modifying antirheumatic
drugs in stable patients with early rheumatoid arthritis of 50.5%, with an increased
risk of non-adherence as the drug treatment scales-up. CONCLUSIONS: The range
of frequencies for drug adherence among diabetic and HIV/AIDS patients varies
widely. This can be attributed to the different methods used to measure adherence
and the lack of a standardized measuring technique. Adherence results are derived
from regional studies; therefore, further research is needed in order to obtain es-
timates with national representation. This is important for the design of drug
policies aimed at enhancing drug adherence to maximize the health benefits from
treatments.
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OBJETIVOS: O objetivo do presente estudo é identificar os principais preditores da
quantidade de medicamentos tomados por indivíduos com doenças crónicas, de
entre diferentes variáveis demográficas, de doença, personalidade, qualidade de
vida e psicossomáticos. MÉTODOS: Participantes são 603 indivíduos, com 41,19
anos de idade média, escolaridades média de 9,87 anos, 72,5% mulheres, portado-
res de uma das seguintes doenças crónicas: epilepsia, diabetes tipo 1 e 2, cancro,
miastenia gravis, esclerose múltipla, obesidade mórbida, com diagnóstico há mais
de três anos. As variáveis avaliadas foram, o número de medicamentos que o
indivíduo toma como variável dependente, e como variáveis independentes,
variáveis psicossociais, tais como, personalidade (neuroticismo e extroversão),
afecto positivo e negativo, componentes mental e físico do SF-36, sintomas psicos-
somáticos (dimensões, sistema nervoso, muscular e digestivo), variáveis demográ-
ficas (idade e escolaridade), e variáveis de doença (numero de anos de diagnóstico,
número de internamentos no último ano, percepção da gravidade da doença).
Recorreu-se à regressão linear hierárquica que incluía o número de medicamentos
tomados como variável dependente e como variáveis independentes, no primeiro
passo as variáveis demográficas, no segundo passo, as variáveis de doença, e no
terceiro as variáveis psicossociais. RESULTADOS: A solução explica 20,6% da
variância da variável dependente. Cada bloco acrescenta valores estatisticamente
significativos à solução. Os resultados sugerem que um quinto da variância na
quantidade de medicamentos tomados é explicada pelas variáveis psicossociais
em que, no modelo final, as variáveis demográficas e de doença são excluídas da
solução. Das variáveis independentes, os principais preditores são, o neuroticismo
(t5,62) os componentes físico e mental do SF-36, (t5,45, e t5,03) e o sistema
nervoso da variável psicossomática (t5,45) todos com um nível de significância
p0,0001.CONCLUSÕES:Um programa de intervenção que melhore a qualidade de
vida é passível de contribuir para a redução na tomada de medicação não essencial.
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MEDICATION USE EVALUATION OF EXPENSIVE AND BROAD-SPECTRUM
ANTIBIOTICS IN SONGKHLA HOSPITAL
Thoedratanaphong OS, Preechavechakul P
Songkhla Hospital, Songkhla, Thailand
OBJECTIVES: To evaluate expensive and broad-spectrum antimicrobials usage in
Songkhla hospital. METHODS: A prospective, chart review was performed on all
inpatients initiated with Levofloxacin, Meropenem, Imipenem/ Cilastatin, Pipera-
cillin/ Tazobactam and Cefoperazone/ Sulbactam from March to December 2010.
Pharmacist interventions were made when medication use evaluation (MUE) cri-
terias were not met and/or drug related problems (DRPs) were detected. RESULTS:
Overall, 347 patients received 412 courses with these antibiotics. Percentage of
empiric therapy was 80 % and specific therapy was 20 %. Pneumonia and sepsis/
septic shock were leading indications of these antibiotic uses. Cefoperazone/Sul-
bactam was the most frequently used. The appropriate use of Levofloxacin, Mero-
penem, Imipenem/Cilastatin, Piperacilin/Tazobactam and Cefoperazone/
Sulbactam was 46%, 40%, 46% 70% and 53% respectively. No indication and
incorrect drug dosage especially in patients with renal impairment were the most
common misuse of these antibiotics. Acceptance of interventions from physician
was 86% (25/29). The cost of inappropriate use of these antibiotics was 28,789 USD.
CONCLUSIONS: MUE program should be continuously performed for effective use
of antibacterial drug, safety and most benefit.
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THE USE OF METHYLPHENIDATE IN A GROUP OF PATIENTS WITH ATTENTION
DEFICIT AND HYPERACTIVITY DISORDER
Gomez-galicia DL1, Rodriguez-fragoso L1, Lopez aymes G1, Sánchez-Alemán M2,
Reyes-esparza JA1
1Universidad Autonoma del Estado de Morelos, Cuernavaca, Morelos, México, 2Instituto Nacional
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OBJECTIVES: to describe the use of stimulants in a group of Mexican children with
ADHD in order to know some pharmacoepidemiological dataMETHODS:An obser-
vational and descriptive study in pediatrics patients based on a survey in a one year
period (June 2009 to June 2010) was done. Survey was answered by children parents
who signed an informed consent. Patients with diagnosis of ADHD and/or received
stimulant treatment with and without co-morbidity were considering. RESULTS:
Of 124 surveys, 85 were selected according to inclusion criteria. 61.2% of patients
received pharmacologic treatment; the drug most use among them was the stim-
ulant methylphenidate (94%). The mean age of stimulant users was 7.94 years (4-13
years), 81.2% were male, 76.5% were in a primary school and 94% had a non-
pharmacologic treatment. The average daily dose was 13.95mg. Immediate release
was the most prescribed form in three different commercial presentations, and 8%
received the long term release. Children with seven years old were who received
more methylphenidate prescription. The age and having a comorbidity increased
the probability (p0.005) for receiving methylphenidate treatment. The most fre-
quent side effect reported was loss of appetite.CONCLUSIONS:Methylphenidate in
an immediate action form was the most prescribed stimulant drug in seven years
old children with ADHD in the population studied. High percentage of children
received methylphenidate treatment.
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